Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 795-798

  Kimura, Sachie ^a   Kuramoto, Kazuya ^a   Homan, Junko ^a   Naruoka, Haruna ^a   Ego, Takeshi ^a   Nogawa, Masaki ^a   Sugahara, Seishi ^a   Naito, Haruna ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Azacitidine; Hypomethylation; Myelodysplastic syndrome; SKM 1; Xenograft model

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLIN DEPENDENT KINASE 4 INHIBITOR B; CYTARABINE; DNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL LINEAGE; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; IC 50; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84858783631     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. INK4B gene in myelodysplastic syndromes. Blood 90: 1403-1409, 1997.
2. INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76: 23-32, 2006.
3. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS, Huang SY, Tsay W, Chen YC, Shen MC, Wang CH, Yeh YC and Tien HF: Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 135: 317-323, 2006. (Pubitemid 44484838)
4. Bernstein BE, Meissner A and Lander ES: The mammalian epigenome. Cell 128: 669-681, 2007. (Pubitemid 46273573)
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach CL and Silverman LR; International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232, 2009.
6. Jones PA, Taylor SM and Wilson VL: Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 84: 202-211, 1983.
7. Taylor SM and Jones PA: Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol 162: 679-692, 1982. (Pubitemid 13113000)
8. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C and MacBeth KJ: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5: e9001, 2010.
9. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA and Holland JF: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429-2440, 2002. (Pubitemid 34525728)
10. Nakagawa T, Matozaki S, Murayama T, Nishimura R, Tsutsumi M, Kawaguchi R, Yokoyama Y, Hikiji K, Isobe T and Chihara K: Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol 85: 469-476, 1993. (Pubitemid 23349047)
11. Nakagawa T and Matozaki S: The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS) - contribution to better understanding of MDS. Leuk Lymphoma 17: 335-339, 1995.
12. Brunning RD, Orazi A, Germing U, Le Beau MM, Prowit A, Baumann I, Vardiman JW and Hellstrom-Lindberg E: Myelodysplastic syndromes. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW (eds.). Lyon, France, IARC Press, pp. 88-103, 2008.
13. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JPJ, Kantarjian HM and Garcia-Manero G: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110: 2302-2308, 2007. (Pubitemid 47523148)
14. Folio MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N, Chiarini F, Ramazzotti G, Baccarani M, Martelli AM, Manzoli L, Martinelli G and Cocco L: Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 106: 16811-16816, 2009.
15. Li LH, Olin EJ, Buskirk HH and Reineke LM: Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 30: 2760-2769, 1970.
16. Kufe DW, Munroe D, Herrick D, Egan E and Spriggs D: Effects of 1-β-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacol 26: 128-134, 1984. (Pubitemid 14035234)
17. Pittillo RF and Woolley C: 5-Azacytidine: microbiological assay in mouse blood. Appl Microbiol 18: 284-286, 1969.